AVCN.TOライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (4 5月 2024 @ 04:59):

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide...

Stats
本日の出来高	156 000
平均出来高	113 572
時価総額	30.69M
EPS	$0 ( 2024-04-01 )
次の収益日	( $0 ) 2024-05-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.06
ATR14	$0.00100 (0.29%)

ボリューム相関

長: -0.48 (neutral)

短: 0.00 (neutral)

Signal:(51.949) Neutral

AVICANNA INC 相関

10 最も正の相関
SJR-B.TO	0.846
HGRO.TO	0.846
CEU.TO	0.845
SSF-UN.TO	0.841
MDA.TO	0.841
NVCN.TO	0.834
OLY.TO	0.827
PFMN.TO	0.827
HSAV.TO	0.82
LAM.TO	0.81

10 最も負の相関
SOY.TO	-0.908
IMV.TO	-0.868
PET.TO	-0.863
QSR.TO	-0.861
IMP.TO	-0.853
HUT.TO	-0.833
AII.TO	-0.83
EXE.TO	-0.828
CGY.TO	-0.825
HLF.TO	-0.824

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

AVICANNA INC 相関 - 通貨/商品

0.00
( neutral )

AVICANNA INC 財務諸表

Annual	2023
収益:	$16.79M
総利益:	$6.58M (39.20 %)
EPS:	$-0.0931

FY	2023
収益:	$16.79M
総利益:	$6.58M (39.20 %)
EPS:	$-0.0931

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$0

FY	2022
収益:	$4.05M
総利益:	$1.12M (27.55 %)
EPS:	$-0.290

Financial Reports:

No articles found.

AVICANNA INC

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.